Hudson Bay Capital Management LP Arrowhead Pharmaceuticals, Inc. Transaction History

Hudson Bay Capital Management LP

$16.3 Billion
Q1 2024

A detailed history of Hudson Bay Capital Management LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 135,000 shares of ARWR stock, worth $3.38 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

135,000

Previous 241,807 44.17%

Holding current value

$3.38 Million

Previous $7.4 Million 47.82%

% of portfolio

0.02%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $2.91 Million - $4.22 Million	-106,807 Reduced 44.17%	135,000 $3.86 Million
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $1.73 Million - $2.54 Million	81,807 Added 51.13%	241,807 $7.4 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $1.24 Million - $1.71 Million	47,500 Added 42.22%	160,000 $4.3 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $880,600 - $1.45 Million	-35,000 Reduced 23.73%	112,500 $4.01 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $3.49 Million - $5.68 Million	147,500 New	147,500 $3.75 Million

Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $933,299 - $1.7 Million	-33,584 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $1.33 Million - $2.35 Million	33,584 New	33,584 $1.55 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $1.16 Million - $1.79 Million	-35,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$26.12 - $43.27 $914,200 - $1.51 Million	35,000 New	35,000 $1.51 Million
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $361,500 - $605,400	-30,000 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $322,200 - $591,000	30,000 New	30,000 $373,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.65B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Arrowhead Pharmaceuticals, Inc. Transaction History